Identification and therapeutic management of highly sensitized patients undergoing renal transplantation

Drugs

Volumn 72, Issue 10, 2012, Pages 1335-1354

  Huber, Lu ^a   Lachmann, Nils ^a   Drr, Michael ^a   Matz, Mareen ^a   Liefeldt, Lutz ^a   Neumayer, Hans H ^a   Schnemann, Constanze ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Alemtuzumab; Atacicept; Azathioprine; Belimumab; Bortezomib; Ciclosporin; Corticosteroids; Eculizumab; Epratuzumab; Everolimus; HLA antigens; Immune globulin; Muromonab CD3; Mycophenolate; Ocrelizumab; Ofatumumab; Renal transplant; Rituximab; Siplizumab; Tacrolimus

Indexed keywords

AZATHIOPRINE; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID; PANEL REACTIVE ANTIBODY; TACROLIMUS;

ANTIBODY DETECTION; ARTICLE; DESENSITIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT SURVIVAL; HEALTH CARE POLICY; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PATIENT CARE; PATIENT IDENTIFICATION; PLASMAPHERESIS; SENSITIZATION;

BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION, IMMUNOLOGIC; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; TISSUE DONORS;

EID: 84863197412     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11631110-000000000-00000     Document Type: Article

References (137)

1. Terasaki PI, Vredevoe DL, Mickey MR, et al. Serotyping for homotransplantations: VII. Selection of kidney donors for thirty-two recipients. Ann N Y Acad Sci 1966; 129: 500-20
2. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts, associated with preexisting humoral antibodies against donor cells. Lancet 1966; 2 (7465): 662-5
3. Lee HM, Hume DM, Vredevoe DL, et al. Serotyping for homotransplantations: IX. Evaluation of leukocyte antigen matching with the clinical course and rejection types. Transplantation 1967; 5 (4 Suppl.): 1040-5
4. Meier-Kriesche HU, Scornik JC, Susskind B, et al. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 2009; 88 (1): 23-9
5. Terasaki P, Lachmann N, Cai J. Summary of the effect of de novo HLA antibodies on chronic kidney graft failure. Clin Transpl 2006: 455-62
6. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87 (10): 1505-13
7. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Eng J Med 2005; 352 (6): 558-69 (Pubitemid 40204669)
8. Zou Y, Stastny P, Susal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Eng J Med 2007; 357 (13): 1293-300 (Pubitemid 47481451)
9. Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87 (4): 549-56
10. Reinsmoen NL, Lai CH, Heidecke H, et al. Antiangiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90 (12): 1473-7
11. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365 (9470): 1570-6 (Pubitemid 40615406)
12. Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int 2011; 79 (6): 655-62
13. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19 (7): 1419-29
14. Poggio ED, Augustine JJ, Clemente M, et al. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83 (7): 847-52 (Pubitemid 46682724)
15. Budde K, Matz M, Durr M, et al. Biomarkers of overimmunosuppression. Clin Pharmacol Ther 2011; 90 (2): 316-22
16. Stastny P, Salvador IM, Lavingia B. Evaluation of the highly sensitized transplant recipient. Pediatr Nephrol 2011; 26 (11): 1927-35
17. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77 (4): 299-311
18. Organ Procurement and Transplantatino Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 annual data report. Rockville (MD): Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2011 [online]. Available from URL: http://www.srtr.org/annual-reports/2010 [Accessed 2011Mar 1]
19. Eurotransplant International Foundation. Annual report 2010. Leiden: Eurotransplant, 2010 [online]. Available from URL: http://www.eurotransplant. org/cms/index. php?page=annual-reports [Accessed 2012 Mar 1]
20. Morath C, Schmidt J, Opelz G, et al. Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch? Langenbecks Arch Surg 2011; 396 (4): 467-74
21. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5 (10): 807-17 (Pubitemid 41400854)
22. Moser K, Tokoyoda K, Radbruch A, et al. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 2006; 18 (3): 265-70
23. Tokoyoda K, Hauser AE, Nakayama T, et al. Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 2010; 10 (3): 193-200
24. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88 (4): 447-52
25. Cai J, Terasaki PI. Current trend of induction and maintenance treatment in positive panel-reactive antibody patients: a report on OPTN/UNOS kidney transplant registry data. Chin Med J (Engl) 2011; 124 (5): 649-54
26. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008; 85 (7): 1046-50 (Pubitemid 351543170)
27. Ntokou IS, Iniotaki AG, Kontou EN, et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transpl Int 2011; 24 (11): 1084-93
28. Mai ML, Ahsan N, Wadei HM, et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 87 (2): 227-32
29. Gjertson DW, Cecka JM. Determinants of long-term survival of pediatric kidney grafts reported to the United Network for Organ Sharing kidney transplant registry. Pediatr Transplant 2001; 5 (1): 5-15 (Pubitemid 32178996)
30. Budde K, Dü rr M. About incidence and timing of donorspecific antibodies after graft nephrectomy. Transplantation 2012 May 15; 93 (9): 865-6
31. Del Bello A, Congy N, Sallusto F, et al. Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation 2012 May 15; 93 (9): 936-51
32. El-Awar N, Terasaki P, Lazda V, et al. Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies. Transplant Proc 2002; 34 (7): 2531-2 (Pubitemid 35304821)
33. Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 2011; 77 (6): 525-34
34. Le Bas-Bernardet S, Hourmant M, Valentin N, et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003; 75 (4): 477-82 (Pubitemid 36241142)
35. Mahoney RJ, Taranto S, Edwards E. B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002; 63 (4): 324-35 (Pubitemid 34303704)
36. Stegall MD, Raghavaiah S, Gloor JM. The [re]emergence of B cells in organ transplantation. Curr Opin Organ Transplant 2010; 15 (4): 451-5
37. Bartel G,Wahrmann M, ExnerM, et al. Determinants of the complement-fixing ability of recipient presensitization againstHLA antigens. Transplantation 2007; 83 (6): 727-33
38. Marti HP, Henschkowski J, Laux G, et al. Effect of donorspecific transfusions on the outcome of renal allografts in the cyclosporine era. Transpl Int 2006; 19 (1): 19-26
39. Roelen DL, van Rood JJ, Brand A, et al. Immunomodulation by blood transfusions. Vox Sang 2000; 78 Suppl. 2: 273-5
40. Cai J, Terasaki PI. The current trend of induction and maintenance treatment in patient of different PRA levels: a report on OPTN/UNOS Kidney Transplant Registry data. Clin Transpl 2010: 45-52
41. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11 (10): 2132-43
42. Cai J, Terasaki PI, Anderson N, et al. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88 (2): 226-30
43. Susal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 2011; 91 (8): 883-7
44. Singh D, Kiberd BA, West KA, et al. Importance of peak PRA in predicting the kidney transplant survival in highly sensitized patients. Transplant Proc 2003; 35 (7): 2395-7 (Pubitemid 37378012)
45. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10 (3): 464-71
46. Susal C, Dohler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol 2009; 70 (8): 569-73
47. Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008; 86 (3): 384-90
48. Mayer G, Persijn GG. Eurotransplant kidney allocation system [ETKAS]: rationale and implementation. Nephrol Dial Transplant 2006; 21 (1): 2-3 (Pubitemid 43057097)
49. Cecka JM. Transplantation: desensitization and transplantation for sensitized patients? Nat Rev Nephrol 2011; 7 (12): 682-3
50. US Department of Health & Human Services. Health Resources and Services Administration. Organ Procurement and Transplantation Network (OPTN). Policy 3.5. Organ distribution: allocation of deceased kidneys. OPTN, 2011 [online]. Available from URL: http://optn.transplant. hrsa.gov/ PoliciesandBylaws2/policies/pdfs/policy-7.pdf [Accessed 2012 Mar 1]
51. Ashby VB, Port FK, Wolfe RA, et al. Transplanting kidneys without points for HLA-B matching: consequences of the policy change. Am J Transplant 2011; 11 (8): 1712-8
52. Duquesnoy RJ, Marrari M. HLAMatchmaker-based definition of structural human leukocyte antigen epitopes detected by alloantibodies. Curr Opin Organ Transplant 2009; 14 (4): 403-9
53. Eurotransplant Reference Laboratory. Donor frequency calculator 2.0 [online]. Available from URL: http://www. etrl.org/FreqDonors/Default.aspx [Accessed 2012 Jun 21]
54. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78 (2): 190-3
55. Sousa LC, Filho HL, Von Glehn Cde Q, et al. EpHLA: an innovative and user-friendly software automating the HLAMatchmaker algorithm for antibody analysis. Transpl Immunol 2011; 25 (4): 210-6
56. Doxiadis II, de Fijter JW, Mallat MJ, et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation 2007; 83 (9): 1207-13 (Pubitemid 46743682)
57. Proust B, Kennel A, Ladriere M, et al. Unexpected anti-HLA-DR and-DQ alloantibodies after nephrectomy of an HLA-DR and-DQ identical first renal transplant. Transpl Immunol 2009; 21 (3): 166-8
58. Tambur AR, Leventhal JR, Friedewald JJ, et al. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90 (10): 1117-24
59. Deng CT, El-Awar N, Ozawa M, et al. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation 2008; 86 (3): 452-9
60. Tran TH, Dohler B, Heinold A, et al. Deleterious impact of mismatching for human leukocyte antigen-C in presensitized recipients of kidney transplants. Transplantation 2011; 92 (4): 419-25
61. Billen EV, Christiaans MH, Doxiadis II, et al. HLA-DP antibodies before and after renal transplantation. Tissue Antigens 2010; 75 (3): 278-85
62. Callender CJ, Fernandez-Vina M, Leffell MS, et al. Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group. Hum Immunol 2012; 73 (2): 175-9
63. Rapaport FT. The case for a living emotionally related international kidney donor exchange registry. Transplant Proc 1986; 18 (3) Suppl. 2: 5-9 (Pubitemid 16086860)
64. Park K, Moon JI, Kim SI, et al. Exchange donor program in kidney transplantation. Transplantation 1999; 67 (2): 336-8 (Pubitemid 29066366)
65. US Renal Data System (USRDS). USRDS 2011 transplant annual report. Minneapolis (MN): USRDS, 2011 [online]. Available from URL: http://www.usrds. org/2011/pdf/v2-ch07-11.pdf [Accessed 2012 Mar 1]
66. de Klerk M, Zuidema WC, JN IJ, et al. Alternatives for unsuccessful living donor kidney exchange pairs. Clin Transpl 2010; 327-32
67. Akkina SK, Muster H, Steffens E, et al. Donor exchange programs in kidney transplantation: rationale and operational details from the north central donor exchange cooperative. Am J Kidney Dis 2011; 57819: 152-8
68. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donorspecific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21 (8): 1398-406
69. Beimler JH, Morath C, Schmidt J, et al. Successful deceased-donor kidney transplantation in crossmatchpositive patients with peritransplant plasma exchange and Rituximab. Transplantation 2009; 87 (5): 668-71
70. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10 (9): 2033-42
71. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2 (8): 758-60 (Pubitemid 36342618)
72. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15 (12): 3256-62 (Pubitemid 39578859)
73. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70 (6): 887-95
74. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76 (10): 1519-25 (Pubitemid 37467706)
75. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6 (2): 346-51 (Pubitemid 43382170)
76. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86 (12): 1754-61
77. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9 (1): 201-9
78. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11 (5): 896-906
79. Garonzik Wang JM, Montgomery RA, Kucirka LM, et al. Incompatible live-donor kidney transplantation in the United States: results of a national survey. Clin J Am Soc Nephrol 2011; 6 (8): 2041-6
80. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6 (4): 922-36
81. Gloor JM, Winters JL, Cornell LD, et al. Baseline donorspecific antibody levels and outcomes in positive crossmatch kidney transplantation.AmJ Transplant 2010; 10 (3): 582-9
82. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Eng J Med 2011; 365 (4): 318-26
83. Haririan A, Nogueira J, Kukuruga D, et al. Positive crossmatch living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9 (3): 536-42
84. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatchpositive living-donor kidney transplantation. Transplantation 2004; 78 (2): 221-7
85. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87 (2): 268-73
86. Lai CH, Cao K, Ong G, et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011; 92 (1): 48-53
87. Kozlowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant 2011; 16 (2): 19-25
88. Habicht A, Broker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients: a single centre experience. Nephrol Dial Transplant 2011; 26 (12): 4124-31
89. Akalin E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibodymediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3 (4): 1160-7
90. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short-and long-term causespecific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13 (3): 769-72 (Pubitemid 34183944)
91. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survi-val, and patient survival after primary kidney transplantation. Transplantation 2003; 76 (9): 1289-93 (Pubitemid 37430713)
92. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7 (11): 2619-25 (Pubitemid 47561615)
93. Morath C, Beimler J, Opelz G, et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25 (5): 506-17
94. Dean PG, Park WD, Cornell LD, et al. Intragraft gene expression in positive crossmatch kidney allografts: ongoing inflammation mediates chronic antibody-mediated injury. Am J Transplant 2012; 12 (6): 1551
95. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6 (8): 1841-7 (Pubitemid 44024955)
96. Anglicheau D, Loupy A, Suberbielle C, et al. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Am J Transplant 2007; 7 (5): 1185-92 (Pubitemid 46643104)
97. Doxiadis II, Duquesnoy RJ, Claas FH. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 2005; 17 (5): 536-40 (Pubitemid 41207958)
98. Lefaucheur C, Antoine C, Suberbielle C, et al. Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11 (8): 1592-8
99. Bingaman AW, Murphey CL, Palma-Vargas J, et al. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86 (12): 1864-8
100. Duquesnoy RJ, Howe J, Takemoto S. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV: an alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 2003; 75 (6): 889-97 (Pubitemid 36373465)
101. Haririan A, Fagoaga O, Daneshvar H, et al. Predictive value of human leucocyte antigen epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. Clin Transplant 2006; 20 (2): 226-33
102. Olausson M, Mjornstedt L, Norden G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7 (1): 130-6 (Pubitemid 44952865)
103. Gutierrez A, Crespo M, Mila J, et al. Outcome of simultaneous liver-kidney transplantation in highly sensitized, crossmatch-positive patients. Transplant Proc 2003; 35 (5): 1861-2 (Pubitemid 37093742)
104. Ingelsten M, Karlsson-Parra A, Granqvist AB, et al. Postischemic inflammatory response in an auxiliary liver graft predicts renal graft outcome in sensitized patients. Transplantation 2011; 91 (8): 888-94
105. Jovicic S, Lezaic V, Simonovic R, et al. Beneficial effects of donor-specific transfusion on renal allograft outcome. Clin Transplant 2011; 25 (2): 317-24
106. Scornik JC, Kriesche HU. Human leukocyte antigen sensitization after transplant loss: timing of antibody detection and implications for prevention. Hum Immunol 2011; 72 (5): 398-401
107. Trucco M, de Petris S, Garotta G, et al. Quantitative analysis of cell surface HLA structures by means of monoclonal antibodies. Hum Immunol 1980; 1 (3): 233-43 (Pubitemid 12234628)
108. Bray RA, Harris SB, Josephson CD, et al. Unappreciated risk factors for transplant patients: HLA antibodies in blood components. Hum Immunol 2004; 65 (3): 240-4 (Pubitemid 38369262)
109. Pfaff WW, Fennell RS, Howard RJ, et al. Planned random donor blood transfusion in preparation for transplantation: sensitization and graft survival. Transplantation 1984; 38 (6): 701-3 (Pubitemid 15183483)
110. Salvatierra Jr O, Vincenti F, Amend W, et al. Deliberate donor-specific blood transfusions prior to living related renal transplantation: a new approach. Ann Surg 1980; 192 (4): 543-52 (Pubitemid 11225438)
111. Siemionow M, Agaoglu G. Role of blood transfusion in transplantation: a review. J Reconstr Microsurg 2005; 21 (8): 555-63 (Pubitemid 41739393)
112. Aalten J, Bemelman FJ, van den Berg-Loonen EM, et al. Pre-kidney-transplant blood transfusions do not improve transplantation outcome: a Dutch national study. Nephrol Dial Transplant 2009; 24 (8): 2559-66
113. Scornik JC, Meier-Kriesche HU. Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant 2011; 11 (9): 1785-91
114. Scornik JC, Ireland JE, Howard RJ, et al. Role of regular and leukocyte-free blood transfusions in the generation of broad sensitization. Transplantation 1984; 38 (6): 594-8 (Pubitemid 15183462)
115. Sanfilippo FP, Bollinger RR, MacQueen JM, et al. A randomized study comparing leukocyte-depleted versus packed red cell transfusions in prospective cadaver renal allograft recipients. Transfusion 1985; 25 (2): 116-9 (Pubitemid 15076903)
116. Karpinski M, Pochinco D, Dembinski I, et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15 (3): 818-24 (Pubitemid 38294813)
117. Scornik JC, Schold JD, Bucci M, et al. Effects of blood transfusions given after renal transplantation. Transplantation 2009; 87 (9): 1381-6
118. Flye MW, Burton K, Mohanakumar T, et al. Donorspecific transfusions have long-term beneficial effects for human renal allografts. Transplantation 1995; 60 (12): 1395-401 (Pubitemid 26012669)
119. Cheigh JS, Suthanthiran M, Fotino M, et al. Minimal sensitization and excellent renal allograft outcome following donor-specific blood transfusion with a short course of cyclosporine. Transplantation 1991; 51 (2): 378-81
120. Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2008 Nov; 74 (10): 1237-40
121. Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007; 84 (2): 137-43 (Pubitemid 47205745)
122. Marrari M, Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl Immunol 2010; 22 (3-4): 105-9
123. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4 (3): 438-43 (Pubitemid 38282302)
124. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients [BENEFIT study]. Am J Transplant 2010; 10 (3): 535-46
125. Liefeldt L, Brakemeier S, Glander P, et al., Eurotransplant al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012 May; 12 (5): 1192-8
126. Willicombe M, Roufosse C, Brookes P, et al. Antibodymediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome. Transplantation 2011; 92 (2): 176-82
127. Brakemeier S, Schweiger B, Lachmann N, et al. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix) in renal transplant recipients. Nephrol Dial Transplant 2012; 27 (1): 423-8
128. Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011; 11 (8): 1727-33
129. Morath C, Beimler J, Opelz G, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010; 90 (6): 645-53
130. Huber L, Naik M, Budde K. Desensitization of HLAincompatible kidney recipients. N Eng J Med 2011; 365 (17): 1643; author reply 4-5
131. Waiser J, Budde K, Schutz M, et al. Comparison between bortezomib and rituximab in the treatment of antibodymediated renal allograft rejection. Nephrol Dial Transplant 2012; 27 (3): 1246-51
132. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12 (5): 1192-8
133. Sutherland SM, Li L, Sigdel TK, et al. Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int 2009; 76 (12): 1277-83
134. Dinavahi R, George A, Tretin A, et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol 2011; 22 (6): 1168-78
135. Trivedi HL, Terasaki PI, Feroz A, et al. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation 2010; 90 (2): 221-2
136. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4 (124): 124ra28
137. National Institute of Allergy and Infectious Diseases (NIAID). Combined kidney and bone marrow transplantation to prevent kidney transplant rejection [Clinical-Trials.gov identifierNCT00801632].USNational Institutes of Health, ClinicalTrials.gov [online]. Available fromURL: http://www.clinicaltrials.gov [Accessed 2012 Jun 18]